Pfizer + Binance dual investment, DeSci’s leading BIO is coming

Author:AB Kuai.Dong

Recently, Binance finally welcomed the first DeSci project. Many old people should have some impression of it, that is, the BIO protocol. From 2018 to the present, the team has continued to build in biological sciences, and has also cooperated to launch new projects, such as URO and RIF.

From the earliest Molecule to today's BIO, 7 years have passed. Apart from the fact that it is known to the outside world that Binance invested in it, how is it?

This article summarizes this.

The founder of BIO is an early OG in the industry. He first did investment analysis in the private equity field. After being exposed to Ethereum in 2016, he started to work as a developer community in South Africa to get involved in Ethereum. During this period, he received funding from relevant organizations.

He then joined Consensys as business development director, and founded Molecule, the predecessor and affiliated company of BIO, in 2018.

According to public information, Molecule initially wanted to try to build an IP trading platform and build its own patent token exchange by tokenizing the patented IP of biopharmaceutical and research companies.

Then, after more outside VCs joined and the market narrative changed, it began to focus on infrastructure, fundraising platforms and business funding.

In September this year, the Solana Foundation provided a donation to Molecule, which ultimately built the Pump Science launch platform to ensure that experimentalists can raise funds for ideas through MEME launches.

At present, the platform has launched Ribactin URO and Urolithin RIF, both of which are Meme disks on Solana.

In addition, BIO also plans to expand the project to the Solana ecosystem to deploy BIO tokens, establish cross-chain bridges, and build related infrastructure. The entire Molecule system is also migrating from Ethereum to Solana.

Behind this, the continued support of the Solana Foundation may be inseparable.

In terms of internal relationships, Molecule is more like the parent company of BIO. In BIO's token white paper this time, 17.6% of the total token supply is attributed to the Molecule Foundation and related investors.

Part of it was also attributed to VitaDAO and VITA IPT holders in response to the community’s controversy about the team’s continuous issuance of new coins.

In terms of market value estimates, BIO's path is reminiscent of CHZ. It once cooperated with various teams to continuously issue new fan tokens, making it a platform for IP transactions and fan economy, while BIO is through Collaborate with scientists to launch DAO tokens in the form of scientific funding.

Currently, BIO plans to launch 15-20 DAO organizations in early 2025. Therefore, the initial market value will be high, and the market will also have expectations for new coins.

However, BIO currently has a lot of community doubts, such as too many internal projects and confusing mutual empowerment and relationships. At the same time, excessive funding and the launch of related DAO tokens may dilute the value of the original circulating tokens, such as URO, RIF and VITA.

People can’t help but think of Animoca, which had crazy investments and projects in its glory days.

After all, there are praises but also doubts. The above is a brief review of BIO, Molecule, and related projects.

This craze of DeSci is actually inseparable from the strong support of CZ and Solana Foundation. They have promoted people's discovery of this narrative. The market is about to enter the January market. In this intensive coin issuance season, for It will be a big test for currency prices.

I hope this content is helpful to you, thanks for reading.